Item 8.01. Other Events. On October 25, 2021, Selecta Biosciences, Inc. (the "Company") entered into a Collaboration and License Agreement (the "Agreement") with Ginkgo Bioworks, Inc., a Delaware corporation, ("Ginkgo"). Under the Agreement, the Company will engage with Ginkgo to design novel and improved enzymes with potentially transformative therapeutic potential to advance treatments for orphan and rare diseases. In return, Ginkgo is eligible to earn both upfront research and development fees and milestone payments, including certain milestone payments in the form of Selecta common stock, clinical and commercial milestone payments of up to $85M in cash, as well as downstream value in the form of royalties on sales.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses